G-III Apparel Group, Ltd. Announces First Quarter Fiscal 2014 Results
-- Net Sales Increase 19% to
-- Results Exceed Guidance with First Quarter Net Income Per Diluted
Share of
-- Full Year Guidance for Net Income Per Diluted Share Increased to
Between
For the quarter ended
Outlook
The Company today revised its prior guidance for the full fiscal 2014
year ending
The Company is now projecting adjusted EBITDA for fiscal 2014 to
increase between 14% and 17%, to between approximately
EBITDA should be evaluated in light of the Company's financial results prepared in accordance with U.S. GAAP. A reconciliation of GAAP net income to adjusted EBITDA is included in a table accompanying the condensed financial statements in this release.
For its second fiscal quarter ending
About
G-III is a leading manufacturer and distributor of outerwear, dresses,
sportswear, swimwear, women's suits and women's performance wear, as
well as luggage and women's handbags, small leather goods and cold
weather accessories, under licensed brands, our own brands and private
label brands. G-III sells swimwear, resort wear and related accessories
under our own Vilebrequin brand. G-III also sells outerwear, dresses,
performance wear and handbags under our own
Statements concerning G-III's business outlook or future economic
performance, anticipated revenues, expenses or other financial items;
product introductions and plans and objectives related thereto; and
statements concerning assumptions made or expectations as to any future
events, conditions, performance or other matters are "forward-looking
statements" as that term is defined under the
(NASDAQGS: GIII) CONSOLIDATED STATEMENTS OF OPERATIONS AND SELECTED BALANCE SHEET DATA |
|||||||||
(In thousands, except per share amounts) |
|||||||||
First Quarter Ended |
|||||||||
(Unaudited) | |||||||||
2013 |
2012 |
||||||||
Net sales | $ | 272,615 | $ | 229,449 | |||||
Cost of sales | 180,223 | 160,759 | |||||||
Gross profit | 92,392 | 68,690 | |||||||
Selling, general and administrative expenses | 85,828 | 66,614 | |||||||
Depreciation and amortization | 3,121 | 2,053 | |||||||
Operating profit | 3,443 | 23 | |||||||
Equity loss in joint venture | - | 286 | |||||||
Interest and financing charges, net | 1,777 |
|
1,104 | ||||||
Income (loss) before taxes | 1,666 | (1,367 | ) | ||||||
Income tax expense (benefit) | 633 | (520 | ) | ||||||
Net income (loss) | 1,033 | (847 | ) | ||||||
Add: Loss attributable to noncontrolling interest | 85 | - | |||||||
Income (loss) attributable to G-III | $ | 1,118 | $ | (847 | ) | ||||
Net income (loss) per common share: | |||||||||
Basic |
$ |
0.06 |
$ |
(0.04 |
) |
||||
Diluted |
$ |
0.05 |
$ |
(0.04 |
) |
||||
Weighted average shares outstanding: | |||||||||
Basic |
20,161 |
19,860 |
|||||||
Diluted |
20,402 |
19,860 |
|||||||
At |
|||||||||
Selected Balance Sheet Data (in thousands): |
2013 |
2012 |
|||||||
Cash | $ | 20,620 | $ | 38,336 | |||||
Working Capital | 276,214 | 291,481 | |||||||
Inventory | 242,072 | 208,755 | |||||||
Total Assets | 664,225 | 532,273 | |||||||
Short-term Revolving Debt | 76,088 | 83,073 | |||||||
Long-term Notes Payable | 19,231 | - | |||||||
Total Stockholders' Equity | 432,100 | 360,472 | |||||||
RECONCILIATION OF FORECASTED AND ACTUAL NET INCOME TO FORECASTED AND ACTUAL ADJUSTED EBITDA |
||||||
(In thousands) |
||||||
(Unaudited) |
||||||
|
Forecasted Twelve Months Ending
|
Actual Twelve Months Ended
|
||||
Net income |
|
|
||||
Expenses associated with Vilebrequin acquisition | - | 3,970 | ||||
Depreciation and amortization | 13,500 | 9,907 | ||||
Interest and financing charges, net | 9,000 | 7,764 | ||||
Income tax expense | 40,700 - 41,900 | 35,436 | ||||
Adjusted EBITDA, as defined |
|
|
||||
Adjusted EBITDA is a "non-GAAP financial measure" which represents
earnings before depreciation and amortization, interest and financing
charges, net, and income tax expense and excludes expenses and
integration costs related to the acquisition of Vilebrequin. The
non-GAAP information in the table above reflects an adjustment for
expenses and integration costs associated with the Vilebrequin
acquisition that were incurred through
For:
Investor Relations
or
Chief Financial Officer
Source:
News Provided by Acquire Media